In a new article published this month in the Journal for ImmunoTherapy of Cancer, we found that improving blood vessel function in glioblastoma tumors with anti-VEGF therapy improved the delivery and efficacy of intravenously delivered CAR-T cells targeting the EGFR-vIII cancer neoantigen. This study uniquely employed syngeneic (immunocompetent) mouse models and mouse CAR-T cells, rather than more commonly used immunocompromised mice with human cells. The combinatorial treatment approach improved intratumoral distribution and anti-tumor activity of these engineered immune cells.